Vera Therapeutics, Inc. (VERA) Stock Price & How to Invest
Last updated November 2026
Short answer
Vera Therapeutics (VERA) is a Nasdaq-listed kidney-disease biotech whose lead drug atacicept, branded TRUTAKNA, won FDA accelerated approval in July 2026 for IgA nephropathy, hit all of its Phase 3 kidney-function endpoints in September, and booked its first sales (about $10.3 million) in Q3 2026, so buying it means owning a newly commercial biotech whose value hinges on how fast it can sell into a crowded market. As of November 20, 2026 the shares closed near $25.64 (market value ~$1.85 billion), down about 47% year to date and near their 52-week low despite the clinical wins.
VERA stock price
As of 2026-11-20, Vera Therapeutics, Inc. (VERA) last closed at $25.45, down 10.6% over the past year. Over the past 52 weeks it has traded between $25.45 and $55.67.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Vera Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.
VERA key stats
At $25.45 on November 20, 2026, Vera Therapeutics, Inc. (VERA) has a market cap of $1.8B.
- Market cap
- $1.8B
- Price to book
- 5.5
- Beta
- 1.19
Market cap, P/E and yield are measured at the $25.45 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Vera Therapeutics, Inc. (VERA)?
The last two weeks for Vera Therapeutics, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- VERA closed at $25.45 on November 20, 2026, down 9.4% over the past five trading days (from $28.10).
Vera Therapeutics, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Vera Therapeutics, Inc. (VERA) do?
Vera Therapeutics is a biotechnology company focused on autoimmune kidney disease. Its lead asset is atacicept (brand name TRUTAKNA, atacicept-vymj), a subcutaneous fusion protein that blocks two B-cell signaling proteins, BAFF and APRIL, which drive the antibody production behind IgA nephropathy (IgAN), a progressive disease that can lead to kidney failure. In the ORIGIN Phase 3 trial, atacicept cut proteinuria (protein leaking into urine, a key marker of kidney damage) by about 46% from baseline and roughly 42% versus placebo at 36 weeks, and on July 7, 2026 the FDA granted accelerated approval, making it the first dual BAFF/APRIL inhibitor cleared for IgAN. In mid-September 2026 Vera reported that the final ORIGIN 3 analysis met all its Phase 3 endpoints: eGFR fell by only about 0.1 mL/min/1.73m2 at 52 weeks on TRUTAKNA versus about 5.7 on placebo, the annualised eGFR decline through 104 weeks was about 0.6 versus 5.6, and there were 11 kidney-progression events versus 38 on placebo. The full results were presented as a late-breaking oral at the opening plenary of ASN Kidney Week 2026, with a simultaneous New England Journal of Medicine publication, and Vera reported a 76% reduction in the risk of composite kidney-disease progression versus placebo through two years. On November 3, 2026 Vera submitted a supplemental BLA for full approval, which it expects in mid-2027, and it plans a European marketing application in the first quarter of 2027.
The investment picture is a classic transition from a de-risked clinical story to an unproven commercial one. Vera booked its first product revenue in Q3 2026: about $10.3 million of TRUTAKNA net sales, well ahead of the ~$3.7 million analysts had expected, with about 700 patient start forms to date by early November. It still posts large net losses typical of a newly launched biotech (about $93.7 million, or $1.30 per share, in Q3 versus ~$1.62 expected, and about $415 million over the trailing twelve months) as selling costs rose to about $61 million a quarter. Cash, equivalents and marketable securities were about $384 million at September 30, 2026, or about $459 million pro forma for a $75 million October debt draw, with up to $350 million more available under its facility subject to conditions. Analysts expect about $22 million of revenue in Q4 2026, about $31 million for 2026 and about $258 million in 2027. The market has been unconvinced so far: the shares closed near $25.64 on November 20, 2026, down about 47% year to date and about 27% over three months, for a market value around $1.85 billion, and Wedbush cut its target to $29 from $34 (neutral) after the Q3 report. The debate is about how quickly Vera can win share in an IgAN market that already has five-plus approved drugs, with Vertex's dual BAFF/APRIL inhibitor povetacicept heading for approval, and whether the full-approval filing leads to a full label in 2027.
What's driving Vera Therapeutics, Inc. (VERA)?
1. TRUTAKNA commercial launch
With accelerated approval in hand since July 7, 2026, Vera has transitioned from a pure clinical-stage company to selling a product. Its first launch quarter, Q3 2026, produced about $10.3 million of net product revenue against a consensus near $3.7 million, and the company reported about 700 patient start forms to date in early November. The pace of prescriber adoption, payer coverage, and revenue in the next several quarters is the single biggest driver of the story from here; analysts expect about $22 million in Q4 2026 and about $40 million in Q1 2027.
2. Full approval and eGFR data
The accelerated approval rested on proteinuria reduction, a surrogate marker. In September 2026 Vera reported that the final ORIGIN 3 analysis met all endpoints, with eGFR essentially stable on TRUTAKNA (about a 0.1 decline at 52 weeks versus about 5.7 on placebo, and an annualised slope of -0.6 versus -5.6 through 104 weeks) and no patients on treatment reaching dialysis or transplant versus eight on placebo. The data were presented at ASN Kidney Week 2026 and published in NEJM. Vera submitted a supplemental BLA for full approval on November 3, 2026 and expects a decision in mid-2027, which would remove the conditional label as an overhang.
3. Dual-mechanism differentiation
Atacicept is positioned as the first therapy to hit both BAFF and APRIL, an upstream B-cell approach distinct from the complement inhibitors and endothelin blockers already on the market. If real-world results match the trial data, that mechanism could support a durable niche in a disease treated with combinations.
4. Pipeline and label expansion
Beyond IgAN, atacicept's B-cell biology is relevant to other autoimmune conditions. Interim results from the PIONEER basket trial in adult IgAN and primary membranous nephropathy were presented at ASN Kidney Week 2026, pediatric IgAN data were shown in a poster, and Vera is evaluating atacicept in other antibody-mediated kidney and autoimmune diseases. A European marketing application is planned for the first quarter of 2027.
What are the risks to Vera Therapeutics, Inc. (VERA)?
Vera has only one quarter of product revenue (about $10.3 million) and funds itself through large operating losses, so it depends on its cash balance (about $384 million at September 30, 2026, or about $459 million pro forma for an October debt draw, against a trailing net loss of about $415 million and nine-month operating cash burn of about $306 million) and capital markets to reach sustained profitability. The IgAN market is already crowded, with atacicept arriving as roughly the sixth approved drug alongside offerings from Novartis, Travere, Otsuka and others, which pressures pricing and share. Vertex's povetacicept, another dual BAFF/APRIL inhibitor whose Phase 3 RAINER trial met its primary endpoint, removes the first-in-class mechanism advantage once it reaches market. The confirmatory eGFR data came in positive in September 2026, but the label stays conditional until the FDA acts on the full-approval filing submitted November 3, with a decision expected in mid-2027. Borrowing under its debt facility adds interest costs and covenants. As a largely single-product company, the stock is highly sensitive to launch execution, competitive dynamics, and safety signals, and its valuation already prices in significant commercial success. The share price has already shown this sensitivity: VERA fell about 47% in 2026 through November 20, reversed lower on the day of its positive ORIGIN 3 news, and kept falling after a Q3 revenue beat; in October 2026 BofA cut its target to $60 from $66 and Leerink initiated at market perform with a $34 target, and in November Wedbush cut its target to $29 from $34.
What is the Vera Therapeutics, Inc. (VERA) forecast?
14 analysts publish price targets on VERA, averaging $71.36 as of November 2026, or +180.4% against the $25.45 share price on November 20, 2026. The published targets run from $29.00 to $100.00, a wide spread, and the ratings split 12 buy, 2 hold, 0 sell. Over the last six months there have been 5 raises and 5 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full VERA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is VERA a buy or a sell?
We give no verdict on Vera Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. TRUTAKNA commercial launch. With accelerated approval in hand since July 7, 2026, Vera has transitioned from a pure clinical-stage company to selling a product. The most optimistic published target, $100.00, assumes this works close to its best case.
The case against. Vera has only one quarter of product revenue (about $10.3 million) and funds itself through large operating losses, so it depends on its cash balance (about $384 million at September 30, 2026, or about $459 million pro forma for an October debt draw, against a trailing net loss of about $415 million and nine-month operating cash burn of about $306 million) and capital markets to reach sustained profitability. The most pessimistic target, $29.00, is roughly what VERA is worth if this bites instead.
Read the full bull and bear case on VERA, including what would have to change to break either one. Walnut is not an investment adviser.
Has Vera Therapeutics, Inc. (VERA) split its stock?
No. Vera Therapeutics, Inc. (VERA) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Vera Therapeutics, Inc. (VERA) valued?
Market cap, P/E and dividend yield at today's price are in the VERA key stats above. The business figures below come from Vera Therapeutics, Inc.'s reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$10.3M (first TRUTAKNA sales, Q3 2026)
- Net loss (Q3 2026): ~$93.7M
- Net loss per share (Q3 2026): ~$1.30 (vs ~$1.62 expected)
- Net loss (TTM): ~$415M
- Cash & marketable securities: ~$384M at Sept. 30, 2026 (~$459M pro forma for an October debt draw)
- 2027 revenue consensus: ~$258M
As of November 2026: As of November 2026, Vera's valuation reflects expectations for atacicept sales rather than current financials: the first launch quarter brought about $10.3 million of revenue against a net loss of about $93.7 million. Its roughly $459 million of pro forma cash, plus further debt capacity, funds the TRUTAKNA launch, though the loss rate shows the runway is finite. Any earnings multiple is not meaningful until commercial revenue builds; at about $1.85 billion the market value sits near 7x the ~$258 million of 2027 revenue analysts expect.
Who competes with Vera Therapeutics, Inc. (VERA)?
Complement inhibitors for IgAN
Novartis markets Fabhalta (iptacopan), a factor B complement inhibitor for IgAN, and other complement-targeting programs are in development. These attack a different part of the disease pathway than atacicept and are among its most direct commercial rivals.
Endothelin and dual-receptor blockers
Travere Therapeutics' Filspari (sparsentan) and Novartis' Vanrafia (atrasentan) reduce proteinuria through endothelin-pathway blockade. They are established, orally dosed options that atacicept must compete against or be combined with in practice.
What stocks are similar to Vera Therapeutics, Inc. (VERA)?
Other names that sit close to VERA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Vera Therapeutics, Inc. (VERA)
There are three common ways to get VERA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so VERA sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where VERA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Vera Therapeutics, Inc. (VERA)
VERA is a freshly approved kidney-drug biotech where the science has now been validated twice (accelerated approval in July, positive ORIGIN 3 eGFR data in September, presented at ASN Kidney Week with an NEJM publication) and the first launch quarter beat expectations, but the stock has fallen about 47% in 2026 on competition and launch questions. The commercial ramp and the full-approval application filed November 3, 2026 (decision expected mid-2027) are the story from here.
More on Vera Therapeutics, Inc. (VERA)
Whether VERA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is VERA a buy or a sell?, and where the stock could go from here in the VERA stock forecast.
For income investors, whether VERA pays a dividend and how the payout looks is covered in does VERA pay a dividend? And to weigh VERA against a peer, read the full side-by-side comparisons: VERA vs NVS and VERA vs TVTX.
Wondering how VERA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Vera Therapeutics, Inc.
Ask Walnut's AI anything about VERA and see how it fits what you own.
FAQ
What does Vera Therapeutics do?
+
Vera Therapeutics is a biotechnology company developing treatments for autoimmune kidney disease. Its lead product, atacicept (branded TRUTAKNA), is a fusion protein that blocks the BAFF and APRIL proteins involved in IgA nephropathy, a progressive kidney disease.
Is TRUTAKNA (atacicept) FDA approved?
+
Yes. On July 7, 2026 the FDA granted accelerated approval to TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk of progression. Full approval depends on confirmatory kidney-function data; those ORIGIN 3 results came in positive in September 2026, Vera submitted its supplemental BLA for full approval on November 3, 2026, and it expects full approval in mid-2027, subject to FDA review.
Does Vera Therapeutics have any revenue?
+
Yes, since the third quarter of 2026. Vera reported no product revenue through June 2026, then about $10.3 million of TRUTAKNA net product revenue in Q3 2026, its first launch quarter, beating the ~$3.7 million analysts expected. It still lost about $93.7 million in the quarter. Analysts expect about $22 million of Q4 revenue and about $31 million for full-year 2026.
How did Vera Therapeutics do in its latest quarter?
+
In Q3 2026, reported November 5, 2026, Vera posted its first TRUTAKNA sales of about $10.3 million, ahead of the ~$3.7 million consensus, and about 700 patient start forms to date. The net loss was about $93.7 million, or $1.30 per share, narrower than the ~$1.62 expected, as launch spending lifted SG&A to about $61 million. Cash and securities were about $384 million at quarter end.
How much cash does Vera have?
+
Vera reported about $384 million in cash, cash equivalents, and marketable securities as of September 30, 2026 (down from roughly $499 million at June 30), or about $459 million pro forma for a $75 million debt draw in October. Up to $350 million more remains available under its debt facility, subject to conditions. Operating cash burn was about $306 million in the first nine months of 2026.
What is IgA nephropathy?
+
IgA nephropathy (IgAN) is a chronic kidney disease in which antibody deposits inflame the kidney's filters, causing protein to leak into urine and, over time, potential kidney failure. It is a leading focus of biotech drug development.
Who are Vera Therapeutics' main competitors?
+
In IgA nephropathy, atacicept competes with Novartis' Fabhalta and Vanrafia, Travere's Filspari, Otsuka's Voyxact, budesonide products like Tarpeyo, and development-stage assets from Vertex and others. It is roughly the sixth approved drug in the space.
Why is VERA's market cap so high with no revenue?
+
As of November 2026 VERA's market capitalization of about $1.85 billion (down from roughly $3 billion in July) reflects investor expectations for future atacicept sales in a large IgAN market rather than current financials. Revenue only began in Q3 2026 (about $10.3 million), so the valuation rests on analysts' forecasts of roughly $258 million of 2027 sales, which is common for a biotech whose lead drug was only just approved.
What are the key upcoming catalysts for VERA?
+
Investors watch the TRUTAKNA launch trajectory (Q4 2026 consensus is about $22 million of revenue), the FDA's review of the full-approval filing submitted November 3, 2026 (decision expected mid-2027), and the European marketing application planned for Q1 2027. Competitor milestones, especially Vertex's povetacicept, could also move the stock in either direction.
What did the ORIGIN 3 kidney-function data show?
+
In September 2026 Vera reported that the final ORIGIN 3 analysis met all Phase 3 endpoints. eGFR declined by about 0.1 mL/min/1.73m2 at 52 weeks on TRUTAKNA versus about 5.7 on placebo, the annualised decline through 104 weeks was about 0.6 versus 5.6, and kidney-progression events numbered 11 versus 38. No treated patients needed prolonged dialysis or a transplant, versus eight on placebo. The results were presented at the opening plenary of ASN Kidney Week 2026 and published in the New England Journal of Medicine, with a 76% reduction in the risk of composite kidney-disease progression versus placebo through two years.
How has VERA stock performed in 2026?
+
As of the November 20, 2026 close near $25.64, VERA was down about 47% year to date, about 27% over three months and about 8% over one year, near the bottom of a 52-week range of roughly $25 to $56. Fourteen analysts had an average target of about $71, though targets have been coming down: BofA trimmed to $60 and Leerink started at $34 in October, and Wedbush cut to $29 in November. Walnut is not an investment adviser; these are historical figures.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Vera Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.